Literature DB >> 3802035

Aromatase activity in primary and metastatic human breast cancer.

A Lipton, S J Santner, R J Santen, H A Harvey, P D Feil, D White-Hershey, M J Bartholomew, C E Antle.   

Abstract

Aromatase activity was measured in 104 primary and 24 metastatic breast cancer patients. The assay employed quantitates the production of 3H water release from 1 beta-[3H]androstenedione after aromatization. Of 104 human primary breast tumors studied, 64 contained measurable aromatase activity, ranging from 5-70.5 pmol estrone formed/g protein/hour. In primary breast cancers there was no difference in levels of aromatase activity when analyzed by menstrual status or age by decade. Aromatase activity was similar in small and large primary tumors. The median aromatase activity of primary breast tumors (8.6 pmol/g/h) was similar to that found in metastatic breast cancer deposits (12.0 pmol/g/h). Aromatase activity did not correlate with either estrogen (ER) or progesterone (PR) receptor concentration in the tissues assayed. In this regard there were 33 ER- PR- tumor biopsies. Twelve of these 33 tumors contained aromatase activity greater than 10 pmol/g/hour.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3802035     DOI: 10.1002/1097-0142(19870215)59:4<779::aid-cncr2820590419>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.

Authors:  Daphne Gschwantler-Kaulich; Anneliese Fink-Retter; Klaus Czerwenka; Gernot Hudelist; Axel Kaulich; Ernst Kubista; Christian F Singer
Journal:  Tumour Biol       Date:  2010-12-29

2.  Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis.

Authors:  A Lipton; R J Santen; S J Santner; H A Harvey; D White-Hershey; M J Bartholomew; F E Sharkey
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

Review 3.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020).

Authors:  B L Nguyen; G Chetrite; J R Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 5.  Letrozole. A review of its use in postmenopausal women with advanced breast cancer.

Authors:  H M Lamb; J C Adkins
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 6.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.

Authors:  G Hudelist; P Wülfing; C Kersting; H Burger; B Mattsson; K Czerwenka; E Kubista; D Gschwantler-Kaulich; A Fink-Retter; C F Singer
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-28       Impact factor: 4.553

8.  Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation.

Authors:  J M Esteban; Z Warsi; M Haniu; P Hall; J E Shively; S Chen
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

9.  Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase.

Authors:  Gui-Jian Liu; Giujian Liu; Yu-Sheen Wu; David Brenin; Wei Yue; Sarah Aiyar; Anne Gompel; Ji-Ping Wang; Rajeshwar Rao Tekmal; Richard J Santen
Journal:  Breast Cancer Res Treat       Date:  2007-11-02       Impact factor: 4.872

Review 10.  The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.

Authors:  Angela Brodie; Vincent Njar; Luciana Furtado Macedo; T Sean Vasaitis; Gauri Sabnis
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.